Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$-0.71
EPS est.
$-0.89
EPS surprise
+20.40%
1-day move
-0.54%
Kymera Therapeutics reported a narrower loss per share than expected, which is a positive sign for the company. However, the stock reacted negatively, declining by 0.5%. This could indicate investor concerns despite the EPS beat, possibly due to the lack of revenue information and guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.71 | $-0.86 | +20.40% |
| Revenue | N/A | $8M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat serious diseases by harnessing the body's own immune system. Operating in the health care sector, its work is significant as it addresses unmet medical needs through targeted protein degradation, a cutting-edge approach in drug development.
Last quarter
In the last quarter, Kymera reported an EPS of -0.97, which was worse than analysts' expectations, leading to a slight decline in stock price. The company has not provided specific revenue figures, making it challenging to assess overall performance.
EPS beat streak
2Q
EPS beat rate
50%
Avg EPS surprise
-5.73%
Avg 1-day reaction
-2.69%
Analysts expect Kymera to report a loss this quarter, with a consensus EPS of -0.86 and revenue of $8 million. The market is watching closely for any signs of improvement in earnings or revenue growth.
Bull case
If Kymera can exceed revenue expectations and narrow its losses, it could signal a turnaround in its business strategy, potentially boosting investor confidence.
Bear case
Conversely, if the company fails to meet these expectations, it may raise concerns about its financial stability and ability to execute its growth plans.
Key metrics to watch
EPS
-0.86Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
8MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Kymera's revenue reach or exceed the $8 million consensus estimate?
Achieving or surpassing this revenue target would indicate strong market demand for its therapies and could positively influence investor sentiment.
Q2
How does management plan to address the ongoing losses reflected in the EPS?
Investors will be keen to hear strategies for improving profitability, as continued losses could raise concerns about the company's long-term viability.
—
Est. EPS
$1.21
Est. Rev
$34.9B
Impl. Move
±5.2%
Why consensus could be wrong
The Street may be underestimating the potential for Kymera to achieve a revenue turnaround, as recent developments in its pipeline could lead to unexpected demand.
Supporting evidence
The options market is pricing a 6.39% move, indicating expectations of volatility that may not align with the company's actual performance.
Kymera's recent insider selling may suggest a lack of confidence in immediate recovery, which could be misinterpreted by the market.
Key risk
If Kymera's revenue comes in significantly above $8 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is currently weighing the potential for recovery against the backdrop of recent disappointing earnings.
Bull confirmed if
Exceeding the consensus EPS of -0.86 and achieving revenue above $8 million would confirm a positive outlook.
Bear confirmed if
Reporting a wider loss than expected or revenue below $8 million would reinforce bearish sentiment.
What the market is pricing for the move.
Implied Move
±6.39%
Historical Avg
±4.2%
The options market is pricing in a significant move around the earnings announcement, suggesting that investors are anticipating volatility.
Options are pricing ±6.4% while KYMR has averaged ±4.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
38.4%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$3.4M
30,000 sh
1 insider
Net
$3.4M
Net selling
Most Active Insiders· 6 open-market trades
$3.4M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
119.36%
of float
Insider
2.12%
of float
Holders
397
institutions
Top Holders· as of Jun 2026
FMR, LLC
12,349,256 sh · $1.3B
14.85%
5.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Kymera beats expectations, history suggests a potential average one-day move of +1.98%, confirming a positive shift in investor sentiment.
In line / cautious
An in-line report could lead to a muted reaction, with management commentary driving the stock's movement as investors assess future guidance.
Miss
If the company misses expectations, history suggests an average one-day move of -4.14%, likely leading to increased skepticism about its growth prospects.
The lines on the call that would change the story.
Recent Transactions
Oct 1, 2026 · @ $115.40
8,230 sh
$949,742.00
Oct 1, 2026 · @ $114.43
7,601 sh
$869,782.43
Oct 1, 2026 · @ $112.42
5,506 sh
$618,984.52
Oct 1, 2026 · @ $113.24
4,876 sh
$552,158.24
Oct 1, 2026 · @ $111.44
3,525 sh
$392,826.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Baker Bros. Advisors, LP
8,657,242 sh · $938.0M
10.41%
Flat
Avoro Capital Advisors LLC
7,474,747 sh · $809.9M
8.99%
Flat
Price (T.Rowe) Associates Inc
7,112,980 sh · $770.7M
8.55%
17.4%
T. Rowe Price Investment Management, Inc.
6,257,261 sh · $678.0M
7.53%
14.5%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.